MUSTANG BIO, INC. Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired
MUSTANG BIO, INC. (MBIO) reported Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired of $9.60 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-29.
Discontinued › Notes
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired · last filed 2018-03-29
- MUSTANG BIO, INC. research and development asset acquired other than through business combination, fair value acquired for fiscal 2017 was $9.60M, a 118.18% increase from fiscal 2016.
- MUSTANG BIO, INC. research and development asset acquired other than through business combination, fair value acquired for fiscal 2016 was $4.40M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 12 month |
|---|---|
| 2017-12-31 | $9.60M 10-K · filed 2018-03-29 |
| 2016-12-31 | $4.40M 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |